code R10.2 is referenced in 12 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island, Blue Cross & Blue Shield of Mississippi, and 3 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R10.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Multiple policy updates are rolling out between February-April 2026, including InterQual criteria changes for molecular diagnostics and procedures, fertility coverage modifications, removal of prior authorization for several genetic testing and continuous glucose monitoring codes, and updated diagnosis code lists for various services.
A hemoglobin (Hgb), hematocrit (Hct), red blood cell count (RBC), or complete blood count (CBC) may be considered medically necessary for listed indications, including bone marrow dysfunction, red blood cell disorders, polycythemia, and other listed conditions. A CBC may be considered medically necessary for listed white blood count and platelet indications and other listed conditions, and these tests are considered not medically necessary for all other indications. On 10/01/2026, the Code Reference section was updated to remove ICD-10 codes B88.0, D71, G35, R10.2, R76.8, and Z84.1 and to add ICD-10 codes including K6A.01, K6A.09, K6A.8, K74.0A, and K76.83.
Effective September 17, 2026, endovascular occlusion of the ovarian and/or internal iliac veins is considered investigational for treating pelvic congestion syndrome. The annual review on that date left the policy intent unchanged. No randomized controlled trials have been published comparing endovascular occlusion for pelvic congestion syndrome with a relevant comparator or sham or placebo treatment, and there is insufficient evidence to conclude a cause and effect relationship between venous congestion and chronic pelvic pain.
Excellus BlueCross BlueShield policy 7.01.10, Sacral Nerve Stimulation, has a current effective date of March 16, 2026. The November 20, 2025 off-cycle review clarified the sacral nerve stimulation trial and permanent placement criteria. Sacral nerve stimulation is medically appropriate for individuals 16 and older who meet both the trial stimulation and permanent placement criteria, and it is considered investigational for stress incontinence, urge incontinence due to a neurological condition, other chronic voiding dysfunction, constipation, chronic pelvic pain and bilateral sacral nerve stimulation.
Independence Blue Cross updated ICD-10 diagnosis codes for Pelvic Floor Therapy services under policy 00.03.06g, effective 10/01/2025. The broad code R10.2 (abdominal pain) was replaced with five more specific subcodes (R10.20, R10.21, R10.22, R10.23, R10.24), and hand therapy diagnosis codes on Attachment A2 (S62.90XA, S62.90XB, S62.91XA, S62.91XB, S62.92XA, S62.92XB) received narrative revisions. Billing teams must update their systems to recognize only the new specific codes for claims reimbursement above capitation for HMO/HMO-POS members.
Aetna's Clinical Policy Bulletin 0735 considers pulsed radiofrequency experimental, investigational, or unproven for all indications in its list, because its effectiveness has not been established. The list includes indications such as carpal tunnel syndrome, chronic knee pain, low back pain, trigeminal neuralgia, and headache. The policy also considers the Stimpod NMS460 nerve stimulator for post-amputation pain, combined ganglion impar block and pulsed radiofrequency for pudendal neuralgia, and combined platelet-rich plasma to the Gasserian ganglion and pulsed radiofrequency for trigeminal neuralgia experimental, investigational, or unproven.
Quantitative sensory testing (QST), current perception threshold (CPT) testing, voltage-actuated sensory nerve conduction threshold (VsNCT) testing, and quantitative thermal testing for early diagnosis of leprosy are considered experimental, investigational, or unproven for the uses listed in this policy, because their effectiveness or clinical value has not been established. Listed uses include evaluating fibromyalgia pain, chronic itch, chronic pelvic pain, and shoulder pain, and diagnosing restless legs syndrome and small fiber neuropathy in postural orthostatic tachycardia syndrome. CPT codes 0106T through 0110T and HCPCS code G0255 are not covered for the listed indications.
Aetna considers pulsed radiofrequency (PRF) experimental, investigational, or unproven for all indications listed in CPB 0735, including carpal tunnel syndrome, chronic knee pain, low back pain, trigeminal neuralgia, and chronic migraine. The policy also lists the Stimpod NMS460 nerve stimulator and a wearable pulsed radiofrequency therapy device for post-amputation pain as experimental, investigational, or unproven, and it gives the same status to combined ganglion impar block and PRF for pudendal neuralgia and to combined platelet-rich plasma to the Gasserian ganglion and PRF for trigeminal neuralgia. There are no specific CPT or HCPCS codes for pulsed radiofrequency, and the policy lists ICD-10 codes that are not covered for the indications listed in the CPB.
Aetna clinical policy bulletin 0805 considers pudendal nerve decompression experimental, investigational, or unproven for indications including chronic pelvic pain, interstitial cystitis, penile numbness and erectile dysfunction, persistent genital arousal disorder, pudendal neuralgia, and vulvodynia. The policy also considers pudendal nerve hydrodissection for chronic pelvic pain syndrome and urinary incontinence, and pudendal neurolysis for persistent genital arousal disorder and pudendal nerve entrapment syndrome, experimental, investigational, or unproven. The policy does not apply to pudendal nerve blocks used in obstetrics and other operative procedures.
Aetna considers dynamic MRI in persons with complex organ prolapse to supplement the physical examination, laparoscopic suture rectopexy for rectal prolapse, Le Fort colpocleisis for severe utero-vaginal prolapse in elderly and chronically ill persons who no longer desire coital function, sacrocolpopexy for vaginal apical prolapse repair, and tension-free vaginal tape for pelvic organ prolapse complicated by stress urinary incontinence medically necessary. Aetna considers biodegradable cog threads, biologic grafts for vaginal apical prolapse, combined laparoscopic-vaginal lateral suspension, pectopexy, laser therapy, transcutaneous electrical nerve stimulation, trans-vaginal absorbable meshes or biological grafts, vNOTES presacral-uterosacral hysteropexy, vNOTES uterosacral ligament suspension, vaginal tactile imaging, and genetic testing experimental, investigational, or unproven for pelvic organ prolapse. The covered CPT codes apply when the selection criteria are met, and specific CPT, HCPCS and ICD-10 codes are listed as not covered for the indications in the policy.
Independence Blue Cross updated TENS policy 05.00.74k to 05.00.74l, replacing the single ICD-10 code R10.2 (Pelvic and perineal pain) with four more specific codes (R10.21, R10.22, R10.23, R10.24) effective 10/01/2025. This is a routine ICD-10 CM coding update to align with current coding specificity requirements; coverage criteria and billing codes remain unchanged.
Aetna's clinical policy bulletin 0805 on pudendal nerve decompression was reviewed on 10/28/2026. It treats pudendal nerve decompression, hydrodissection and neurolysis as experimental, investigational or unproven for chronic pelvic pain, pudendal neuralgia, interstitial cystitis, penile numbness and erectile dysfunction, persistent genital arousal disorder and vulvodynia, and it lists three related CPT codes as not covered for those indications. The source does not state an effective date for a change or describe a coverage change in this review.
Watch R10.2
Get one email when a payer policy names R10.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.